Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
1,041.51
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump
↗
December 19, 2025
Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday.
Via
Investor's Business Daily
Topics
Government
Stocks
The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era
December 19, 2025
As the final weeks of 2025 unfold, the biotechnology sector is undergoing a fundamental transformation, shifting from a pure-play innovation market to one increasingly dictated by the "physical"...
Via
MarketMinute
Topics
Earnings
Economy
Intellectual Property
Mounjaro Maker Eli Lilly Improves In Quality As BofA Sees 'Room For Stock Upside' With $3 Billion In Sales By 2026
↗
December 19, 2025
Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.
Via
Benzinga
1 No-Brainer Growth S&P Index Fund to Buy Right Now for Less Than $500
↗
December 18, 2025
This is a quick and easy way to invest in growth.
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
Stocks
Better Buy in 2026: UnitedHealth Group or Eli Lilly?
↗
December 18, 2025
These industry titans have gone in opposite directions this year; is that likely to change?
Via
The Motley Fool
Topics
Fraud
The 2022 Playbook Returns: Why Investors are Building a 'Fortress 2026'
December 18, 2025
As the calendar turns toward 2026, the exuberant "AI-everything" rally that defined much of 2024 and 2025 is facing a sobering reality check. With the Federal Reserve entering a delicate transition...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
World Trade
Worried About the Stock Market in 2026? These 3 Stocks Did Well During the Last Bear Market.
↗
December 18, 2025
The stocks listed here were all up more than 19% in 2022, while the S&P 500 crashed.
Via
The Motley Fool
Topics
Intellectual Property
Stocks
New Obesity Medicine Association Initiative Aims to Scale High-Impact Obesity Healthcare Improvements Nationwide
December 18, 2025
Centennial, Colorado--(Newsfile Corp. - December 18, 2025) - The Obesity Medicine Association (OMA) is pleased to announce a new multi-phase...
Via
Newsfile
Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics
↗
December 18, 2025
Lilly’s Orforglipron is eligible for a fast-track review by the FDA in treating obesity.
Via
Stocktwits
Better Buy in 2026: Pfizer or Eli Lilly?
↗
December 18, 2025
These two stocks have been going in opposite directions over the past few years.
Via
The Motley Fool
Topics
World Trade
Main Street’s High-Stakes Gamble: Retail Traders Double Down as Inflation Cools to 2.7%
December 18, 2025
NEW YORK — In a stunning reversal of the "higher-for-longer" narrative that dominated much of 2025, the Bureau of Labor Statistics released its November Consumer Price Index (CPI) report today,...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Regulatory Compliance
Why Eli Lilly (LLY) Stock Is Trading Up Today
December 18, 2025
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.2% in the morning session after the company released positive data from its Phase 3 "ATTAIN-MAINTAIN" trial, which evaluated the...
Via
StockStory
After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss
↗
December 18, 2025
Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.
Via
Benzinga
The Weight of a Trillion: Inside Eli Lilly’s Pharmaceutical Hegemony
December 18, 2025
On this day in late 2025, Eli Lilly and Company (NYSE: LLY) stands as the undisputed titan of the global pharmaceutical industry. Having crossed the historic $1 trillion market capitalization threshold...
Via
PredictStreet
Topics
Economy
World Trade
Eli Lilly's Weight-Loss Pill Succeeds In A First-Of-Its-Kind Study
↗
December 18, 2025
Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off.
Via
Investor's Business Daily
Eli Lilly Scores Another Major Win: Time to Buy?
↗
December 18, 2025
The company is running circles around its competition.
Via
The Motley Fool
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk
↗
December 18, 2025
These two healthcare stocks have strong growth prospects, but they've been going in opposite directions.
Via
The Motley Fool
The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now
↗
December 17, 2025
It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.
Via
The Motley Fool
Topics
Intellectual Property
1 Cash-Producing Stock for Long-Term Investors and 2 We Brush Off
December 16, 2025
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via
StockStory
3 Unstoppable Vanguard ETFs to Buy Even if There's a Stock Market Sell-Off in 2026
↗
December 16, 2025
These three growth stock-heavy ETFs offer a contrarian way to invest in a potential stock market sell-off.
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
Economy
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector
December 16, 2025
New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall...
Via
MarketMinute
Topics
Intellectual Property
1 Bold Prediction for Viking Therapeutics in 2026
↗
December 16, 2025
Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it.
Via
The Motley Fool
Is Eli Lilly a Buy Before 2026?
↗
December 16, 2025
Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.
Via
The Motley Fool
3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most
↗
December 16, 2025
Via
MarketBeat
Profit Powerhouse: Strong Earnings Outlook Defies Market Slips, Signaling Continued Bull Run for US Stocks
December 16, 2025
Despite recent pockets of volatility and "slips" in the U.S. stock market during late 2025, a robust corporate profit outlook is emerging as a powerful counter-narrative, fueling investor optimism and...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Pfizer Adds to Its Big Bet on Weight Loss Drugs
↗
December 16, 2025
Via
MarketBeat
Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars
↗
December 16, 2025
Novo Nordisk's stock has dropped 41% YTD as it lowered sales growth and trimmed 2025 guidance due to competition and patent expiration.
Via
Benzinga
Topics
Intellectual Property
Where Will Eli Lilly Be in 10 Years?
↗
December 16, 2025
In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.
Via
The Motley Fool
Topics
Intellectual Property
2 Predictions for Eli Lilly in 2026
↗
December 15, 2025
Can anything stop this high-flying drugmaker?
Via
The Motley Fool
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years
↗
December 15, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.